Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.82 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.82 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.82 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.82 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.82 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL120616 | 1.00 | CYP2D6 (1.00) | CYP2D6MAPTBLMLMNAHTT | |
| Dextrorphan SCHEMBL30546365 | 1.00 | CYP2D6 (1.00) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL17598076 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL29363177 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL194174 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL443051 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL120615 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL10688552 | 0.98 | CYP2D6 (0.96) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL31276780 | 0.93 | CYP2D6 (0.87) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL28614888 | 0.92 | OPRD1 (0.89) | CYP2D6MAPTBLMLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116626212-A | Quantitative analysis method of sinomenine in biological sample | 湖南正清制药集团股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-20190008848-A1 | IDENTIFICATION OF ADDITIONAL ANTI-PERSISTER ACTIVITY AGAINST BORRELIA BURGDORFERI FROM AN FDA DRUG LIBRARY | THE JOHNS HOPKINS UNIVERSITY | 2019-01-10 | — | — | US | claimed |
| WO-2017034984-A1 | IDENTIFICATION OF ADDITIONAL ANTI-PERSISTER ACTIVITY AGAINST BORRELIA BURGDORFERI FROM AN FDA DRUG LIBRARY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-02 | — | — | WO | claimed |
| US-20080070939-A1 | LOCAL ANESTHETIC COMPOSITIONS CONTAINING DEXTROROTATORY MORPHINAN DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CHI MEI FOUNDATION HOSPITAL (TW) | 2008-03-20 | — | — | US | claimed |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | ZEVRA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2024123700-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116626212-A | Quantitative analysis method of sinomenine in biological sample | 湖南正清制药集团股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-6263237-B1 | Techniques for treating anxiety disorders by brain stimulation and drug infusion | MEDTRONIC, INC. | 2001-07-17 | — | — | US | disclosed |
| US-6227203-B1 | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion | MEDTRONIC, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6176242-B1 | Method of treating manic depression by brain infusion | MEDTRONIC, INC. | 2001-01-23 | — | — | US | disclosed |
| EP-0617618-A1 | ARYL-TRIFLATES AND RELATED COMPOUNDS | WIKSTRÖM, Hakan Vilhelm (NL) | 1994-10-05 | — | — | EP | disclosed |
| EP-0219896-B1 | Pharmaceutical compositions on the basis of dextrorphan for intranasal application | PRODOTTI FORMENTI (IT) | 1993-11-03 | — | — | EP | disclosed |
| WO-1993011761-A1 | ARYL-TRIFLATES AND RELATED COMPOUNDS | H. LUNDBECK A/S (DK) | 1993-06-24 | — | — | WO | disclosed |
| US-5019579-A | Antitussive Agents | PRODOTTI FORMETI S.R.L. (IT) | 1991-05-28 | — | — | US | disclosed |
| EP-0219896-A1 | Pharmaceutical compositions on the basis of dextrorphan for intranasal application | PRODOTTI FORMENTI S.r.l. (IT) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | OPRM1 2/4885CYP2D6 31/4885MAPT 1585/4885 |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | HTR5A, CHRNA5, HTR1A | OPRM1 93/4885CYP2D6 180/4885MAPT 737/4885 |
| US-20080070939-A1 | LOCAL ANESTHETIC COMPOSITIONS CONTAINING DEXTROROTATORY MORPHINAN DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | OPRM1, OPRD1, CYP2D6 | OPRM1 1/4885CYP2D6 3/4885MAPT 540/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | OPRM1 57/4885CYP2D6 405/4885MAPT 776/4885 |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885CYP2D6 19/4885MAPT 1333/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | OPRM1 824/4885CYP2D6 4706/4885MAPT 446/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | OPRM1 769/4885CYP2D6 4684/4885MAPT 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.